Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective study
Main finding · 30-day mortality (multivariable analysis)Result — go to the resultHazard ratio 1.07 95% CI 0.59–1.93Authors' conclusion
The use of a molecular syndromic panel in patients with VABP was able to impact antibiotic decisions, without an unfavorable effect on mortality.
Study context
- Population
- Intensive care units (ICU) patients with ventilator-associated bacterial pneumonia (VABP)
- Participants
- 237 patients
- Exposure
- Molecular syndromic panel plus culture vs culture only
- Outcome
- Mortality from VABP onset
- Follow-up
- 30 days
Methodological detailsmulticentre, MULTI-SITA platform
- Multicentre
- MULTI-SITA platform
Main finding
30-day mortality (multivariable analysis)
Hazard ratio
1.07
95% CI 0.59–1.93
P = 0.825
Molecular syndromic panel vs Culture only
HR 1.07 (95% CI 0.59–1.93); P = 0.825
As reported in the abstract
- SOFA score associated with increased mortality
- HR 1.13 1.13 (95% CI 1.04-1.22, p = 0.003)
- Previous carbapenem-resistant Pseudomonas aeruginosa isolation associated with increased mortality
- HR 3.02 3.02 (95% CI 1.25-7.32, p = 0.015)
- Solid neoplasm associated with increased mortality
- HR 2.15 2.15 (95% CI 1.12-4.14, p = 0.022)
Observational data: associations, not effects.
Further findings
De-escalation or initiation of appropriate antibiotic therapy · day 1 from VABP onset
P = 0.041
Original publication
Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective study. Crit Care. Published 25 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →